RT Journal Article
SR Electronic
T1 Regulatory T-cells are central hubs for age-, sex- and severity-associated cellular networks during COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.01.06.22268711
DO 10.1101/2022.01.06.22268711
A1 Søndergaard, Jonas N.
A1 Tulyeu, Janyerkye
A1 Edahiro, Ryuya
A1 Shira, Yuya
A1 Yamaguchi, Yuta
A1 Murakami, Teruaki
A1 Morita, Takayoshi
A1 Kato, Yasuhiro
A1 Hirata, Haruhiko
A1 Takeda, Yoshito
A1 Okuzaki, Daisuke
A1 Sakaguchi, Shimon
A1 Kumanogoh, Atsushi
A1 Okada, Yukinori
A1 Wing, James B.
YR 2022
UL http://medrxiv.org/content/early/2022/01/06/2022.01.06.22268711.abstract
AB Using single-cell proteomics by mass cytometry, we investigate changes to a broad selection of over 10,000,000 immune cells in a cohort of moderate, severe, and critical Japanese COVID-19 patients and healthy controls with a particular focus on regulatory T-cells (Tregs). We find significant disruption within all compartments of the immune system and the emergence of atypical CTLA-4high CD4 T-cells and proliferating HLA-DRlowCD38high Tregs associated with critical patients. We also observed disrupted regulation of humoral immunity in COVID-19, with a loss of circulating T follicular regulatory T cells (Tfr) and altered T follicular helper (Tfh)/Tfr and plasma cell/Tfr ratios, all of which are significantly lower in male patients. Shifting ratios of CXCR4 and CXCR5 expression in B-cells provides further evidence of an autoimmune phenotype and dysregulated humoral immunity. These results suggest that Tregs are central to the changing cellular networks of a wide range of cells in COVID-19 and that sex specific differences to the balance of Tfr, Tfh and plasma cells may have important implications for the specificity of the humoral immune response to SARS-CoV-2.Competing Interest StatementThe authors have declared no competing interest.Funding StatementJapan Society for the Promotion of Science, Kakenhi 19H01021, 20K21834 (YO) Japan Agency for Medical Research and Development: JP21km0405211, JP21ek0109413, JP21ek0410075, JP21gm4010006, and JP21km0405217 (YO) JST Moonshot R&D: JPMJMS2021, JPMJMS2024 (YO) Takeda Science Foundation: (YO) Bioinformatics Initiative of Osaka University Graduate School of Medicine, Osaka University: (YO) IFReC grant program for next generation principal investigators (JBW) Japan Society for the Promotion of Science 16H06295 (SS) Japan Agency for Medical Research and Development JP19gm0010005 (SS) Leading Advanced Projects for Medical Innovation (SS) Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All participants provided written informed consent as approved by the ethical committees of Osaka University Graduate School of Medicine, and affiliated institutes.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors